Pascal Seitz

Pascal Seitz

Auto-generated profile, based on publicly available information

Pascal Seitz

Klinik für Rheumatologie und Immunologie, Inselspital, Universitätsspital Bern, Anna-Seiler-Haus, Bern, Schweiz

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
PSPascal Seitz
Pascal Seitz
JCJennifer Cullmann
Jennifer Cullmann
SBSusana Bucher
Susana Bucher
LBLukas Bütikofer
Lukas Bütikofer
SRStephan Reichenbach
Stephan Reichenbach
LSLuca Seitz
Luca Seitz
Objectives: To investigate the proportion and distribution of contrast enhancement (CE) of musculoskeletal structures with MRI of the thorax/abdomen/pelvis in giant cell arteritis (GCA). Methods: CE at 34 musculoskeletal sites was rated with a four-point ordinal scale. Patients were divided into groups with or without glucocorticoid (GC) treatment and with or without symptoms of polymyalgia rheumatica (PMR). Two composite scores were created: an MRI score, including seven sites, and a limited MRI score, including four sites. Results: Retrospectively, 90 consecutive patients with GCA were included. The population included 54 and 36 patients with and without PMR symptoms, respectively, and 45 (50%) patients were receiving GCs at the time of MRI. CE was found in 90.7% of lumbar spines, 87.5% of the pelvis, 82.2% of shoulder girdles and in 95.6% at any site in patients without GCs. The proportion of patients without and with GCs with at least moderate enhancement was, respectively, 91.1% and 75.6% at ≥1–3 sites, 75.6% and 51.1% at ≥4–6 sites, and 64.4% and 28.9% at ≥7–9 sites. The mean difference between the proportion of pathological CE in patients with and without GCs was 27.4% for synovial sites and 18.3% for periarticular/musculotendinous sites. Both composite scores captured substantial differences between groups, and correlation was very strong between scores. Conclusion: MRI shows CE of musculoskeletal structures typical of PMR in most patients with GCA, supporting the concept of ‘GCA-PMR spectrum disease’. Changes are more frequent at periarticular/musculotendinous sites and in the presence of PMR symptoms. A clear response to GCs is evident, less so for periarticular/musculotendinous sites.

1 March 2024 in Swiss Medical Weekly
Verified
Journal Article
Open access
PDF file
LWLouis Wolff
Louis Wolff
LCLeo Caratsch
Leo Caratsch
FLFabian Lötscher
Fabian Lötscher
LSLuca Seitz
Luca Seitz
PSPascal Seitz
Pascal Seitz
Denis ComteDenis Comte
Denis Comte
STUDY AIMS: VEXAS syndrome is a recently discovered monogenic auto-inflammatory disease caused by a somatic mutation in the UBA1 gene that manifests with rheumatologic and haematologic features. In this report, we present the first Swiss cohort, detailing its manifestations and treatment outcomes among Swiss patients. METHODS: Data were retrospectively collected from nine hospitals across Switzerland, representing a broad geographic distribution. Treating physicians completed a standardised case report form for each patient. The principal investigator and the co-investigators collected and analysed all case report forms. RESULTS: We identified 23 patients between July 2022 and 2023, of which 17 are described. All were male. They presented with skin manifestations (88%), general symptoms (82%), venous thromboembolism (59%), ocular manifestation (59%), lung infiltrates (59%) and articular manifestations (47%). Central nervous system and kidney manifestations were very rare, and heart and digestive manifestations were absent. Macrocytic anaemia was present in all patients throughout the disease progression but only in two-thirds of patients (12/17, 71%) at the time of diagnosis. Clinical response was reached in all cases treated with ruxolitinib (4/4, 100%), upadacitinib (1/1, 100%), azacytidine (5/5, 100%) and haematopoietic stem cell transplantation (2/2, 100%). All deaths were attributed to infections (5/5, 100%). CONCLUSION: This study corroborates the clinical spectrum of VEXAS syndrome described in other cohorts. It suggests that VEXAS syndrome is not limited to patients with macrocytic anaemia. In this study, azacytidine has been used effectively among patients with myelodysplastic syndrome. In addition, Janus kinase (JAK) inhibitors, particularly ruxolitinib, have been successfully used even in those without myelodysplastic syndrome. We report two successful treatments by haematopoietic stem cell transplantation.

1 July 2025 in Frontiers in Radiology
Verified
Journal Article
Open access
PDF file
PSPascal Seitz
Pascal Seitz
SBSusana Bucher
Susana Bucher
LBLukas Bütikofer
Lukas Bütikofer
BMBritta Maurer
Britta Maurer
HBHarald Marcel Bonel
Harald Marcel Bonel
LSLuca Seitz
Luca Seitz
Objectives: To compare two established scoring schemes for the 2D-T1-weighted “black-blood” MRI sequence (T1-BB) for superficial cranial arteries (SCA) in the diagnosis of giant cell arteritis (GCA).Methods: Ten arterial segments were evaluated in T1-BB images with two different methods: a visual semiquantitative scheme (T1-BB-VISUAL) and a composite scheme that included both the semiquantitative assessment and a quantitative wall thickness measurement (T1-BB-COMP). The expert clinical diagnosis after ≥6 months of follow-up was the diagnostic reference standard. Diagnostic accuracy and agreement on the segment and patient levels were evaluated for the two different rating schemes.Results: Retrospectively, 151 consecutive patients with clinically suspected GCA were included. The study cohort consisted of 82 patients with and 69 without GCA. For the T1-BB-COMP and the T1-BB-VISUAL, the sensitivity was 81.7% vs. 87.8% (p = 0.025), the specificity was 91.3% vs. 88.4% (p = 0.16) and the proportion of correct diagnoses was 86.1% vs. 88.1% (p = 0.26), respectively. The overall agreement between the two methods for 1,201 rated arterial segments was very good at 91.6% with a kappa of 0.80. The agreement was higher for segments with a larger calibre than for smaller segments: common superficial temporal arteries 98.0%, occipital arteries 93.2%, frontal branches 89.8% and parietal branches 86.9%. The correlation of wall thickness measurements between readers was strong (Spearman's rho of 0.68). The time needed to apply the T1-BB-VISUAL was about half as long as for the T1-BB-COMP (4.5 vs. 8.95 minutes).Conclusion: In suspected GCA, the additional measurement of the wall thickness of SCAs in 2D-T1-BB MRI does not lead to a better diagnostic performance compared to visual semiquantitative scoring alone. Visual scoring is preferred due to higher efficiency and reliability.

17 July 2024 in Rheumatology
Verified
Journal Article
Closed access
PDF file
RZRoberto Ziliotti
Roberto Ziliotti
LSLuca Seitz
Luca Seitz
MGMatthias Gasser
Matthias Gasser
PSPascal Seitz
Pascal Seitz
A 52-year-old man, with a history of inflammation of unknown origin, myalgias, migratory thrombophlebitis, thrombocytopenia and anaemia presented with right-sided pain in the neck and preauricular region and a CRP of 270 mg/l. Head MRI with T1-fatsat black blood vessel wall and diffusion weighted imaging showed inflammation around the right superficial temporal vessels ( Fig. 1A–D) [ 1]. GCA was suspected, but ultrasound, including spectral Doppler analysis, identified the vein as the culprit lesion with a marked circumferential thickening of the venous vessel wall ( Fig. 1E). Ultrasound revealed neither a halo nor a compression sign in the temporal arteries. MRI images were carefully reassessed and confirmed the vein as the affected vessel. Venous biopsy had previously been performed at the forearm with confirmed phlebitis. Bone marrow biopsy showed myelodysplasia and pronounced vacuolization of myeloid precursors. The detection of a UBA1-gene mutation (c.118-2A>C) led to the diagnosis of VEXAS (vacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic) syndrome [ 2]. Ultimately, bone marrow transplantation was necessary 6 months after diagnosis and the patient is doing well without any ongoing treatment.

26 June 2026 in BMJ Case Reports
Verified
Journal Article
Closed access
RZRoberto Ziliotti
Roberto Ziliotti
LSLuca Seitz
Luca Seitz
NBNicolas Bonadies
Nicolas Bonadies
YBYara Banz
Yara Banz
PSPascal Seitz
Pascal Seitz
A man in his 50s receiving immunomodulatory therapy for presumed Behçet’s disease presented with odynophagia and jaw pain. Three months earlier, he had developed deep vein thrombosis and extensive superficial phlebitis with transmural inflammation on histopathology. Imaging revealed carotid artery vasculitis and unilateral inflammation around the temporal vessels. Ultrasound demonstrated wall thickening of the right temporal vein with normal temporal arteries. Persistent systemic inflammation and bicytopenia prompted bone marrow examination revealing myelodysplastic syndrome. Detection of a somatic UBA1 mutation confirmed VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic). Glucocorticoids and interleukin-1 blockade were initiated. Due to severe cytopenia, the patient underwent allogeneic haematopoietic stem cell transplantation, resulting in clinical remission. VEXAS causes variable vessel vasculitis, affecting arteries and veins alike even without thrombosis. In older men with myelodysplasia or cytopenia, VEXAS should be considered in the differential of both venous and arterial vasculitis. Ultrasound may distinguish temporal phlebitis from giant cell arteritis.

22 October 2026 in Zeitschrift für Rheumatologie
Verified
Journal Article
Open access
PDF file
PSPascal Seitz
Pascal Seitz
Zusammenfassung: Bei den idiopathischen inflammatorischen Myopathien (IIM) sind abgesehen von der relativ häufig bestehenden Dysphagie gastrointestinale Manifestationen selten und wenig bekannt. Die oropharyngeale oder ösophageale Dysphagie bei IIM ist mit Aspiration und Malnutrition assoziiert. Sie spricht mit Ausnahme der Dysphagie bei „inclusion body myositis“ gut auf konventionelle Immunmodulation an. Die seltene intestinale Vaskulopathie bei NXP2-assoziierter Dermatomyositis bei Kindern und Erwachsenen führt zu lebensbedrohlichen Perforationen und Blutungen vom Ösophagus bis zum Dickdarm und ist daher mit einer hohen Mortalität verbunden. Sie spricht nicht gut auf konventionelle Immunmodulation an. In den letzten Jahren zeigten experimentelle Therapieansätze mit Januskinase(JAK)-Inhibitoren (durch Interferon-Hemmung), Vedolizumab und dem C5-Inhibitor Eculizumab jedoch vielversprechende Resultate. Die ebenfalls seltene Pneumatosis cystoides intestinalis zeigt sich durch gasgefüllte Zysten in der Submukosa v. a. von Dünn- und Dickdarm und ist bei IIM häufig aber nicht immer ein asymptomatischer Zufallsbefund, der konservativen Maßnahmen zugänglich ist. IIM können mit Dys- und Hypomotilität im gesamten Gastrointestinaltrakt verbunden sein, wobei am Darm Pseudoobstruktion und bakterielle Überwucherung mit Malnutrition entstehen können. Wichtig zu beachten ist, dass bei IIM mit erhöhter Kreatinkinase auch Aspartat-Aminotransferase (ASAT) und Alanin-Aminotransferase (ALAT) aus dem Skelettmuskel freigesetzt werden und eine Transaminasen-Erhöhung daher praktisch nie Ausdruck einer Hepatopathie ist.